GC Genome Statistics

Total Valuation

GC Genome has a market cap or net worth of KRW 182.11 billion. The enterprise value is 144.85 billion.

Market Cap	182.11B
Enterprise Value	144.85B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

GC Genome has 23.65 million shares outstanding. The number of shares has increased by 12.46% in one year.

Current Share Class	23.65M
Shares Outstanding	23.65M
Shares Change (YoY)	+12.46%
Shares Change (QoQ)	+13.47%
Owned by Insiders (%)	15.52%
Owned by Institutions (%)	n/a
Float	10.20M

Valuation Ratios

The trailing PE ratio is 65.04.

PE Ratio	65.04
Forward PE	n/a
PS Ratio	5.91
PB Ratio	2.42
P/TBV Ratio	2.44
P/FCF Ratio	443.15
P/OCF Ratio	263.46
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 35.38, with an EV/FCF ratio of 352.47.

EV / Earnings	59.33
EV / Sales	4.70
EV / EBITDA	35.38
EV / EBIT	127.85
EV / FCF	352.47

Financial Position

The company has a current ratio of 8.57, with a Debt / Equity ratio of 0.06.

Current Ratio	8.57
Quick Ratio	8.16
Debt / Equity	0.06
Debt / EBITDA	1.03
Debt / FCF	10.28
Interest Coverage	3.44

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	1.43%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, GC Genome has paid 209.55 million in taxes.

Income Tax	209.55M
Effective Tax Rate	7.90%

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	7,142.20
200-Day Moving Average	n/a
Relative Strength Index (RSI)	64.27
Average Volume (20 Days)	89,340

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, GC Genome had revenue of KRW 30.79 billion and earned 2.44 billion in profits. Earnings per share was 118.39.

Revenue	30.79B
Gross Profit	14.07B
Operating Income	1.13B
Pretax Income	2.65B
Net Income	2.44B
EBITDA	4.09B
EBIT	1.13B
Earnings Per Share (EPS)	118.39

Full Income Statement

Balance Sheet

The company has 41.49 billion in cash and 4.22 billion in debt, giving a net cash position of 37.26 billion or 1,575.59 per share.

Cash & Cash Equivalents	41.49B
Total Debt	4.22B
Net Cash	37.26B
Net Cash Per Share	1,575.59
Equity (Book Value)	75.18B
Book Value Per Share	3,196.61
Working Capital	46.90B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 691.24 million and capital expenditures -280.29 million, giving a free cash flow of 410.95 million.

Operating Cash Flow	691.24M
Capital Expenditures	-280.29M
Free Cash Flow	410.95M
FCF Per Share	17.38

Full Cash Flow Statement

Margins

Gross margin is 45.71%, with operating and profit margins of 3.68% and 7.93%.

Gross Margin	45.71%
Operating Margin	3.68%
Pretax Margin	8.61%
Profit Margin	7.93%
EBITDA Margin	13.30%
EBIT Margin	3.68%
FCF Margin	1.33%

Dividends & Yields

GC Genome does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.46%
Shareholder Yield	-12.46%
Earnings Yield	1.34%
FCF Yield	0.23%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

GC Genome has an Altman Z-Score of 12.69 and a Piotroski F-Score of 3.

Altman Z-Score	12.69
Piotroski F-Score	3